Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.09.2012 | short review

Treating T-cell lymphoma: is there a light at the end of the tunnel?

verfasst von: Georg Hopfinger, Olaf Merkel, Thomas Melchardt, Richard Greil

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

Treating peripheral T-cell lymphomas (PTCL) remains a clinical challenge harbouring an often aggressive course and furthermore, no standard therapy is established. In more detail, PTCL comprises a heterogeneous group of haematological tumours constituting less than 15 % of all non-Hodgkin’s lymphomas (NHLs) in adults in the western hemisphere. The following short review will provide an up-date based on data presented at ASH meeting 2011 in PTCL providing improved understanding of patho-mechanism and further development of more specific therapy options.
Vorheriger Artikel ASH 2011—Hodgkin’s disease and the high grade lymphomas
Nächster Artikel ASH update 2011: chronic lymphocytic leukemia and indolent lymphoma
Literatur
1.
Swerdlow SH, Campo E, Harris NL, et al. (eds.) WHO Classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC. 2008;2(2):439.
2.
Foss FM, Zinzani PL, Vose JM, et al. Peripheral T-cell lymphoma. Blood. 2011 Jun 23;117(25):6756–67.PubMedCrossRef
3.
Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008 Sept 1;26(25):4124–30.PubMedCrossRef
4.
Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, et al. ALK− anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the international peripheral T-cell lymphoma project. Blood. 2008 Jun 15;111(12):5496–504.PubMedCrossRef
5.
Tang T, Allen G, Koo GC, Tay K, Tan D, Quek R, et al. Gene expression profiling identifies the JAK/STAT and NF kappa B pathways to be important in peripheral T-cell lymphomas and natural-killer T-cell lymphomas. Blood. 2011 Nov 18;118(21):1142 (#2658).
6.
Martin-Sanchez E, Rodriguez-Pinilla SM, Lombardia L, Dominguez-Gonzalez B, Sanchez-Beato M, Romero D, et al. PI3 K inhibition as a potential therapeutic strategy in peripheral T-cell lymphomas. Blood. 2011 Nov 18;118(21):1490–1 (#3494).
7.
Marchi E, Kalac M, Bongero DC, McIntosh CM, Fogli LK, Scotto L, et al. Combination of epigenetic agents synergistically reverse the malignant phenotype in models of T-cell lymphoma. Blood. 2011 Nov 18;118(21):1173 (#2727).
8.
Merkel O, Hamacher F, Laimer D, Sifft E, Trajanoski Z, Scheideler M, et al. Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK+ and ALK−) anaplastic large-cell lymphoma. Proc Natl Acad Sci U S A. 2010 Sept 14;107(37):16228–33.PubMedCrossRef
9.
Piccaluga PP, Laginestra MA, Rossi M, De Leo A, Gibellini D, Gazzola A, et al. Identification of differentially expressed miRNAs in peripheral t-cell lymphomas. Blood. 2011 Nov 18;118(21):350–1 (#773).
10.
Schmitz N, Trumper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German high-grade non-Hodgkin lymphoma study group. Blood. 2010 Nov 4;116(18):3418–25.PubMedCrossRef
11.
Gallamini A, Zaja F, Patti C, Billio A, Specchia MR, Tucci A, et al. Alemtuzumab (Campath-1 H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood. 2007 Oct 1;110(7):2316–23.PubMedCrossRef
12.
Kim JG, Sohn SK, Chae YS, Cho YY, Yang DH, Lee JJ, et al. Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study. Cancer Chemother Pharmacol. 2007;60(1):129–34.CrossRef
13.
Dunleavy K, Shovlin M, Pittaluga S, Grant C, Steinberg SM, Jaffe ES, et al. DA-EPOCH chemotherapy is Highly effective in ALK-positive and ALK-negative ALCL: results of a prospective study of PTCL subtypes in adults. Blood. 2011 Nov 18;118(21):704 (#1618).
14.
Reimer P, Rudiger T, Geissinger E, Weissinger F, Nerl C, Schmitz N, et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J Clin Oncol. 2009 Jan 1;27(1):106–13.PubMedCrossRef
15.
Rodriguez J, Conde E, Gutierrez A, Arranz R, Leon A, Marin J, et al. Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from the Gel-Tamo study group. Eur J Haematol. 2007 Jul;79(1):32–8.PubMedCrossRef
16.
d’Amore F, Relander T, Lauritzsen GF, Jantunen E, Hagberg H, Anderson H, et al. High-dose chemotherapy and autologuos stem cell transplantation in previously untreated peripheral T-cell lymphoma—final analysis of a large prospective multicenter study (NLG-T-01). Blood. 2011 Nov 18;118(21):155–6 (#331).
17.
d’Amore F, da Silva MG, Leppa S, Relander T, Pezzutto A, Lauritzsen GF, et al. First interim safety analysis of a phase III randomized trial in newly diagnosed systemic peripheral T-cell lymphoma treated with CHOP chemotherapy with or without alemtuzumab and consolidated by autologous hematopoietic stem cell transplant. Blood. 2011 Nov 18;118(21):1755 (#4110).
18.
O’Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B, et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011 Mar 20;29(9):1182–9.PubMedCrossRef
19.
Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012 Feb 20;30(6):631–6.PubMedCrossRef
20.
Dupuis J, Casasnovas RO, Morschhauser F, Ghesquieres H, Thieblemont C, Ribrag V, et al. Early results of a phase Ib/II dose-escalation trial of romidepsin in association with CHOP in patients with peripheral T-cell lymphomas (PTCL). Blood. 2011 Nov 18;118(21):1148 (#2673).
21.
Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010 Nov 4;363(19):1812–21.PubMedCrossRef
22.
Advani RH, Shustov AR, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma: a phase 2 study update. Blood. 2011 Nov 18;118(21):204 (#443).
23.
Friedberg J, Mahadevan D, Jung J, Persky DO, Lossos IS, Danaee H, et al. Phase 2 trial of alisertib (MLN8237), an investigational, potent inhibitor of aurora A kinase (AAK), in patients (pts) with aggressive B- and T-cell non-Hodgkin lymphoma (NHL). Blood. 2011 Nov 18;118(21):46 (+#95).
Metadaten
Titel
Treating T-cell lymphoma: is there a light at the end of the tunnel?
verfasst von
Georg Hopfinger
Olaf Merkel
Thomas Melchardt
Richard Greil
Publikationsdatum
01.09.2012
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2012
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-012-0013-4

Weitere Artikel der Ausgabe 3/2012

New drugs for head and neck cancer

  • short review

Current treatment of low grade gliomas

  • Open Access
  • review

Brief update on recent developments in CML

  • short review

Follow-up care for head and neck cancer patients

  • short review

Primary central nervous system lymphoma: update and current approach

  • short review

New developments in MDS

  • short review